Cavli Wireless Is Set to Unveil the Next Generation of LPWAN-based IoT with C42GM Smart Cellular IoT Module at Embedded World 2022, Germany.
17.6.2022 13:31:00 EEST | Business Wire | Press release
Cavli Wireless will participate in the Embedded World 2022 edition in Nuremberg, Germany, from June 21-23, 2022. The Embedded World event is the world's biggest trade fair for everything Embedded, from electronic systems, distributed intelligence, the Internet of Things, e-mobility, energy efficiency, and much more. The company will be exhibiting its IoT connectivity solutions in hall 5, booth no: 5-362.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220617005168/en/
Powering the next generation of LPWAN IoT with Cavli C42GM Smart Cellular IoT Module (Graphic: Business Wire)
The premier showcase at the Cavli booth will be the new launch of the C42GM LTE CAT M1/NB1/NB2 compatible Smart Cellular IoT Module, which can be deployed across the globe, making it an ideal solution for logistics, automotive, vehicle tracking systems, and more.
C42GM is a dual-mode LTE CAT M1/NB1/NB2 (upgradable to Release 14) compatible Smart Cellular Module, based on 3GPP Release 13, that comes with an integrated eSIM. C42GM has a battery life profile of ten years due to Deep Sleep Mode capability. It also comes with integrated GNSS and Sigfox radio capability that can equip OEMs to explore use cases that need the hybrid LPWAN approach. As John Mathew, Chief Technology Architect at Cavli Wireless, quoted, “the integrated eSIM coupled with pre-loaded global connectivity further cements the C42GM as the world's most powerful LPWAN-based cellular IoT module."
By virtue of the Hubble Stack Intelligence, C42GM can be managed via Hubble Lens, an advanced remote diagnosis feature of the Cavli Hubble IoT Management platform wherein a customer or a Cavli Support Engineer can remotely diagnose, monitor & debug the field device with zero physical intervention, thereby paving the way for the true scaling of IoT.
Due to Cavli’s strong operator partnerships in the EU, we have an extensive footprint across Europe for our local LTE as well LTE-M connectivity offering, which is unparalleled in the industry in terms of service quality & pricing.
Join Cavli Wireless on June 22 at 16:00 GMT and participate in the exhibitor's forum where Thomas Fesquet, Business Engagement Manager for Cavli Wireless will be unveiling C42GM for our European customers & technology partners visiting the Embedded World event. Watch this video by Cavli Wireless for more information https://www.youtube.com/watch?v=DfyRiYjpkdM
"The Embedded World 2022 event is the premier trade fair for technology companies from around the globe to present their flagship offerings," said Tarun Thomas George, Chief Operating Officer at Cavli Wireless. "We are beyond excited to be a part of this prestigious event, share the stage alongside industry heavyweights, and demonstrate to the world how Cavli Wireless is democratizing the Internet of Things."
About Cavli Wireless
Cavli Wireless designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite development processes for various applications. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users affordable international data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
About Embedded World
Every year, the Embedded World Exhibition & Conference in Nuremberg offers the embedded community the opportunity to learn about innovations, exchange ideas, and maintain and establish valuable contacts. Exhibitors present state-of-the-art on all facets of embedded technologies, from components, modules, and complete systems to operating systems and software, hardware and software tools, and services related to embedded systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005168/en/
Contact information
Ajit Thomas, CMO, Cavli Wireless Inc
ajit@cavliwireless.com
+1-650-535-1150
https://www.cavliwireless.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom